Home Newsfeeds Benchmark Maintains Buy on Builders FirstSource, Raises Price Target to $115

Benchmark Maintains Buy on Builders FirstSource, Raises Price Target to $115

Benchmark analyst Reuben Garner maintains Builders FirstSource (NYSE:BLDR) with a Buy and raises the price target from $95 to $115.

byBenzinga Newsdesk

March 1, 2023

1 minute read

Benchmark analyst Reuben Garner maintains Builders FirstSource (NYSE:BLDR) with a Buy and raises the price target from $95 to $115.

P/E Ratio Insights for Apple

By Benzinga Insights

May 1, 12:30 PM

In the current session, the stock is trading at $169.97, after a 0.17% spike. Over the past month,…

AAPL

CymaBay Initiates AFFIRM, A Phase 3b/4 Study Evaluating The Effect Of Seladelpar On Clinical Outcomes In Patients With Cirrhosis Due To Primary Biliary Cholangitis

By Benzinga Newsdesk

September 21, 8:08 AM

AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar's accelerated

CBAY

Ketamine Therapy: Revitalist’s New Financing Option, Irwin Naturals Expands Chain Of Clinics

By Lara Goldstein

November 1, 2:19 PM

Revitalist Increases Patient Access By Financing Costs With M-Lend Financial

IWINF

XORTX Announces Completion Of Screening And Enrollment In Bridging Pharmacokinetics Study

By Benzinga Newsdesk

November 28, 8:01 AM

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat

TSXV:XRTX

Benchmark Maintains Buy on Builders FirstSource, Raises Price Target to $115

Related Posts

P/E Ratio Insights for Apple

CymaBay Initiates AFFIRM, A Phase 3b/4 Study Evaluating The Effect Of Seladelpar On Clinical Outcomes In Patients With Cirrhosis Due To Primary Biliary Cholangitis

Ketamine Therapy: Revitalist’s New Financing Option, Irwin Naturals Expands Chain Of Clinics

XORTX Announces Completion Of Screening And Enrollment In Bridging Pharmacokinetics Study